Eight Metabolic Pathways: Decoding Cancer’s Bioenergetic Reprogramming

Metabolic reprogramming is a defining feature of cancer biology. Beyond genetic instability, malignant cells reshape nutrient uptake, energy production, biosynthesis, redox control, and stress adaptation to support proliferation, survival, immune evasion, and therapy resistance.

Introduction

Metabolic reprogramming represents one of the fundamental hallmarks of cancer, enabling malignant cells to sustain uncontrolled growth, resist apoptosis, and adapt to hostile tumor microenvironments. While early cancer research focused heavily on mutations in oncogenes and tumor suppressors, it is now clear that many genetic alterations converge on metabolic pathways that rewire cellular energetics and biosynthesis.

Tumor cells differ from their normal counterparts not only through genomic instability, but also through profound shifts in how they acquire, process, and utilize nutrients. This metabolic plasticity allows cancer cells to proliferate under hypoxia, nutrient limitation, oxidative stress, and immune pressure.

Modern oncology has entered an era of metabolic precision medicine. Inhibitors targeting metabolic enzymes such as IDH1/2, FASN, and GLS1 have reached clinical evaluation, while metabolic signatures are increasingly used to stratify patients and predict therapeutic response.

Overview of Eight Cancer Metabolic Pathways

This review highlights eight critical metabolic pathways—HK2, GLS1, FASN, SHMT2, IDH1/2, ULK1, MCT4, and G6PD—that together define the bioenergetic architecture of malignant transformation. Understanding these pathways helps connect oncogenic signaling, tumor metabolism, immune modulation, and therapeutic vulnerability.

HK2: Glycolysis and the Warburg Effect

Hexokinase 2 (HK2) catalyzes the first committed step of glycolysis by phosphorylating glucose to glucose-6-phosphate, trapping it within the cell for energy production and anabolic biosynthesis. In most normal tissues, HK1 predominates, whereas tumor cells often preferentially express HK2.

HK2 can associate with the outer mitochondrial membrane through the voltage-dependent anion channel (VDAC). This localization facilitates access to ATP and helps shield the enzyme from feedback inhibition. The Warburg effect describes the use of glycolysis for ATP generation even under aerobic conditions, supporting rapid biomass synthesis and generating intermediates for nucleotide and amino acid biosynthesis.

Overexpression of HK2, driven by oncogenic MYC, HIF-1α, and PI3K/AKT signaling, is a defining feature of highly glycolytic tumors such as glioblastoma and hepatocellular carcinoma. Pharmacologic inhibition of HK2 with small molecules such as 2-deoxy-D-glucose and lonidamine has shown promise, although systemic glucose utilization creates toxicity challenges.

GLS1: Glutamine Addiction and Anaplerotic Flux

Glutaminase 1 (GLS1) converts glutamine to glutamate, providing carbon and nitrogen for nucleotide, amino acid, and lipid biosynthesis. Many cancer cells exhibit “glutamine addiction,” relying on this pathway to replenish tricarboxylic acid (TCA) cycle intermediates through anaplerosis.

MYC-driven cancers, including triple-negative breast cancer and pancreatic adenocarcinoma, can show elevated GLS1 expression. This helps maintain mitochondrial oxidative phosphorylation, even under stressful conditions such as hypoxia. Inhibiting GLS1 deprives tumor cells of α-ketoglutarate, increasing oxidative stress and impairing proliferation.

Telaglenastat (CB-839), a selective GLS1 inhibitor, has advanced to phase II clinical trials and has been explored in combination with mTOR and PD-1 blockade strategies. Recent studies also suggest that GLS1 inhibition may alter macrophage metabolism toward a more pro-inflammatory phenotype, highlighting the connection between glutamine metabolism and antitumor immunity.

FASN: Lipid Synthesis and Tumor Growth

Fatty acid synthase (FASN) catalyzes the de novo synthesis of palmitate from acetyl-CoA and malonyl-CoA, consuming substantial amounts of NADPH. Although FASN activity is relatively low in many adult tissues, it is reactivated in numerous cancers to support membrane biogenesis, energy storage, and oncogenic signaling.

FASN overexpression has been associated with poor prognosis in prostate, breast, and ovarian cancers. The lipogenic phenotype provides metabolic autonomy under nutrient scarcity and supports membrane remodeling required for proliferation and metastasis.

Inhibition of FASN can induce ER stress and apoptosis, particularly in tumors dependent on lipid biosynthesis, including HER2-positive and PI3K-mutant cancers. Several FASN inhibitors, including TVB-2640 and TVB-3166, have entered clinical evaluation.

SHMT2: One-Carbon Metabolism and Nucleotide Biosynthesis

Serine hydroxymethyltransferase 2 (SHMT2) operates within the mitochondrial one-carbon metabolism pathway. It converts serine into glycine while transferring one-carbon units to tetrahydrofolate. These reactions provide precursors for purine and thymidylate synthesis, as well as methyl donors for epigenetic regulation.

In rapidly proliferating tumor cells, SHMT2 is transcriptionally upregulated by HIF-1α and c-MYC. This supports nucleotide biosynthesis and helps maintain redox balance through NADPH generation. SHMT2 also buffers oxidative stress by coupling formate production with mitochondrial respiration.

Inhibiting SHMT2 can impair DNA synthesis and sensitize cancer cells to antifolates such as methotrexate and pemetrexed. Dual inhibition of SHMT2 and MTHFD2 is emerging as a strategy for overcoming resistance in folate-dependent malignancies.

IDH1/2: Oncometabolite Production and Epigenetic Dysregulation

Isocitrate dehydrogenase 1 and 2 (IDH1/2) catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate in the cytoplasm and mitochondria, respectively. Mutant IDH1/2 enzymes acquire neomorphic activity, converting α-ketoglutarate into the oncometabolite D-2-hydroxyglutarate (2-HG).

Elevated 2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases, including TET DNA demethylases and histone demethylases. This causes genome-wide hypermethylation and blocks cellular differentiation.

IDH1/2 mutations are hallmark events in gliomas, acute myeloid leukemia (AML), and chondrosarcomas. Targeted inhibitors such as ivosidenib for IDH1 and enasidenib for IDH2 can restore differentiation and achieve durable responses in AML, representing a paradigm for metabolically targeted epigenetic therapy.

ULK1: Autophagy and Metabolic Plasticity

Unc-51-like kinase 1 (ULK1) initiates autophagy, a catabolic process that degrades cellular components to maintain metabolic homeostasis under stress. ULK1 activation by AMPK and inhibition by mTOR form a critical nutrient-sensing switch.

In cancer, autophagy plays dual roles. It can suppress tumor formation in early stages by preventing genomic instability, but it may also promote survival in established cancers by sustaining energy supply and mitigating oxidative damage.

ULK1 supports metabolic flexibility by allowing cancer cells to recycle lipids and amino acids when external nutrients are limited. Inhibition of ULK1 with compounds such as SBI-0206965 or MRT68921 has been investigated as a way to sensitize tumors to chemotherapy and mTOR inhibitors.

MCT4: Lactate Signaling and the Tumor Microenvironment

Monocarboxylate transporter 4 (MCT4, SLC16A3) mediates lactate export from glycolytic tumor cells, helping maintain intracellular pH and regenerate NAD⁺ for continued glycolysis. Lactate, once considered merely a metabolic waste product, is now recognized as a signaling molecule that can influence angiogenesis, immune evasion, and metastasis.

Tumor-derived lactate acidifies the microenvironment and contributes to immune suppression by inhibiting cytotoxic T cells and NK cells while enhancing M2 macrophage polarization. MCT4 upregulation is driven by HIF-1α and NF-κB under hypoxia, helping establish metabolic symbiosis between glycolytic and oxidative cancer cells.

Pharmacologic inhibition of lactate transport using agents such as syrosingopine or AZD3965 may disrupt lactate shuttling and contribute to energetic collapse in hypoxic tumors. Combination strategies with PD-1 inhibitors are being studied to determine whether neutralizing acidosis can improve immune infiltration.

G6PD: Redox Balance and NADPH Homeostasis

Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the rate-limiting step of the pentose phosphate pathway (PPP), generating NADPH for biosynthetic reactions and redox maintenance. NADPH is essential for neutralizing reactive oxygen species and maintaining reduced glutathione levels.

G6PD overexpression can confer oxidative stress resistance and support fatty acid synthesis, particularly in KRAS-driven lung and pancreatic cancers. Enhanced PPP flux has been linked to chemoresistance and metastatic potential.

Inhibiting G6PD or NADPH regeneration may sensitize tumor cells to oxidative stress and radiotherapy. Compounds such as polydatin and DHEA derivatives have been investigated for their ability to suppress G6PD activity in cancer models.

Conclusion

Metabolic reprogramming constitutes a major pillar of precision oncology, alongside signal transduction targeting and immune checkpoint modulation. The eight metabolic pathways discussed—glycolysis through HK2, glutaminolysis through GLS1, lipid synthesis through FASN, one-carbon metabolism through SHMT2, oncometabolite production through IDH1/2, autophagy through ULK1, lactate signaling through MCT4, and redox balance through G6PD—collectively form the biochemical infrastructure sustaining tumor growth and survival.

These pathways demonstrate that cancer metabolism is not simply a consequence of proliferation. It is an active driver of oncogenesis, therapeutic resistance, and immune modulation. Integrative strategies that target metabolic vulnerabilities while preserving systemic homeostasis may offer opportunities for durable efficacy.

Emerging technologies such as metabolomics, stable isotope tracing, and single-cell metabolic profiling are mapping tumor heterogeneity with increasing resolution. Artificial intelligence is also enabling predictive modeling of metabolic flux, helping guide personalized intervention strategies.

As metabolic precision medicine matures, its success will depend on understanding not only which pathways are altered, but also how and when they are rewired during the tumor lifecycle. Decoding these adaptive networks may help move cancer therapy beyond static inhibition toward dynamic control—transforming metabolism from a hallmark of cancer into a therapeutic vulnerability.

References

1. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Nature Reviews Cancer 24, 1–20 (2024).
2. Altman B.J., et al. Glutamine metabolism in cancer: from nutrient sensing to therapeutic targeting. Cell Metabolism 37(2), 241–260 (2025).
3. Röhrig F., Schulze A. The multifaceted roles of fatty acid synthase in cancer. Trends in Cancer 10(3), 189–203 (2024).
4. Ducker G.S., Rabinowitz J.D. One-carbon metabolism in health and disease. Nature Reviews Molecular Cell Biology 26, 221–240 (2025).
5. Losman J.A., Kaelin W.G. IDH mutations and oncometabolite 2-hydroxyglutarate: from mechanism to therapy. Annual Review of Cancer Biology 9, 127–150 (2025).
6. Amaravadi R., et al. Autophagy and cancer: current challenges and future directions. Nature Reviews Molecular Cell Biology 25, 712–735 (2024).
7. Faubert B., et al. Lactate metabolism in the tumor microenvironment: an energetic and signaling nexus. Cancer Metabolism 13, 87–108 (2025).
8. Patra K.C., Hay N. The pentose phosphate pathway and cancer. Trends in Biochemical Sciences 50(1), 15–33 (2025).